Adjuvant therapy with low-dose interferon-beta for stage II and III melanoma: results of a retrospective analysis

Clin Exp Dermatol. 2017 Oct;42(7):781-785. doi: 10.1111/ced.13179. Epub 2017 Jun 25.

Abstract

Interferon (IFN)-alfa as an adjuvant therapy has been found to improve relapse-free survival in patients with malignant melanoma (MM). However, the efficacy of IFN-beta has not been studied in detail. This study evaluated the contribution of adjuvant IFN-beta therapy to improvements in the prognosis of patients with MM. We reviewed 63 patients with resected stage II/III primary MM at our institution. Of these, 36 had been treated with IFN-beta adjuvant therapy (subcutaneous injection, 3 × 106 IU/day, 10 days), while 27 patients had undergone observation alone. In comparisons of all patients (stage II/III), overall survival and relapse-free survival were significantly better in the IFN-beta group than in the observation group (P < 0.001 for both). The 75-month overall survival rate was 41.2% in the observation group and 68.7% in the IFN-beta group. Adjuvant therapy with IFN-beta may become a new treatment option for patients with stage II/III MM.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Chemotherapy, Adjuvant
  • Disease-Free Survival
  • Female
  • Humans
  • Injections, Subcutaneous
  • Interferon-beta / therapeutic use*
  • Kaplan-Meier Estimate
  • Male
  • Melanoma / drug therapy*
  • Melanoma / mortality
  • Melanoma / surgery
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies
  • Skin Neoplasms / drug therapy*
  • Skin Neoplasms / mortality
  • Skin Neoplasms / surgery
  • Survival Rate

Substances

  • Antineoplastic Agents
  • Interferon-beta